Уважаемые коллеги, доброго времени суток! Представляем вам китайское научное издание Cancer Biology and Medicine. Журнал имеет второй квартиль, издается в Chinese Anticancer Association, находится в открытом доступе, его SJR за 2019 г. равен 1,927, печатный ISSN - 2095-3941, предметные области - Исследования рака, Онкология. Вот так выглядит обложка:
Редактором является Хи Чан Хао, контактные данные - editor@cancerbiomed.org
https://www.researchgate.net/profile/Xi_Shan_Hao
Это рецензируемое издание открытого доступа Китайской противораковой ассоциации (CACA), которая является ведущим профессиональным обществом онкологии в Китае. Журнал ежеквартально предоставляет инновационную и значимую информацию о биологических основах рака, микроокружении рака, трансляционных исследованиях рака и всех аспектах клинических исследований рака. Журнал также публикует важные перспективы развития терапии местных видов онкологии в Китае. Язык публикации английский.
Пример статьи, название - The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency. Заголовок (Abstract) -
Objective: The newly defined cancer-testis (CT) gene, MEIOB, was previously found to play key roles in DNA double-strand break(DSB) repair. In this study, we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negativebreast cancers (TNBCs).
Methods: The Cancer Genome Atlas database was used to quantify the expression of MEIOB. Cox regression analysis was used toevaluate the association between MEIOB expression and the prognosis of human TNBC. The effects of MEIOB on cell proliferationand migration in TNBCs were also assessed in vitro. Patient-derived xenograft (PDX) models were used to assess the sensitivity ofbreast cancers with active MEIOB to PARP1 inhibitors.
Results: We confirmed MEIOB as a CT gene whose expression was restricted to the testes and breast tumors, especially TNBCs. Itsactivation was significantly associated with poor survival in breast cancer patients [overall, hazard ratio (HR) = 1.90 (1.16–2.06);TNBCs: HR = 7.05 (1.16–41.80)]. In addition, we found that MEIOB was oncogenic and significantly promoted the proliferationof TNBC cells. Further analysis showed that MEIOB participated in DSB repair in TNBCs. However, in contrast to its function inmeiosis, it mediated homologous recombination deficiency (HRD) through the activation of polyADP-ribose polymerase (PARP)1by interacting with YBX1. Furthermore, activated MEIOB was shown to confer sensitivity to PARP inhibitors, which was confirmedin PDX models.
Conclusions: MEIOB played an oncogenic role in TNBC through its involvement in HRD. In addition, dysregulation of MEIOBsensitized TNBC cells to PARP inhibitors, so MEIOB may be a therapeutic target of PARP1 inhibitors in TNBC.
Keywords: Cancer-testis gene; MEIOB; triple-negative breast cancer; PARP1 inhibitor; cell proliferation